Takeaways from 2022 ‘Meet Novartis Management’ event
23/09/22 -"Novartis again shared a reassuring outlook, with promising sales growth and margin expansion targets. The only difference now is that the firm has clarity on Sandoz and all its efforts can be ..."
Pages
71
Language
English
Published on
23/09/22
You may also be interested by these reports :
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...
23/04/24
The Q1 results came in ahead of the consensus as growth was supported by healthy performances across all the focus areas. Consequently, the ...
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...